Systemair’s Q3 report offered some surprises, mainly related to sales in the various regions where o...
Solwers' Q4 sales were weak, 11% below our expectation, and EBITA of EUR 1.
Redeye reinforces its positive view of Lime following the CMD.
Alzecure förbereder sedan en länge tid en fas 2a-studie med bolagets innovativa projekt ACD856, en s...
Administer delivered a clear profitability beat in Q4 despite continued top-line headwinds.
Solwers reported its results for Q4 with sales of EUR 20.
Yesterday evening, Hansa Biopharma announced a PDUFA date of 19 December, indicating a standard rath...
Cicor reported H2 2025 sales of CHF 235.8m (2% vs. NDA and Bloomberg consensus), up 34.
Redeye has updated its estimates following Heliospectra’s Q4 2025 report.
Redeye is impressed by Safeture’s new partnership deal that was announced yesterday.
Although we see that Leaddesk’s ARR was negatively impacted by regulatory changes in some European c...
Leaddesk's Q4 continued to follow the trends of previous quarters.
Administer's Q4 results were mixed, with net sales declining slightly more than we had estimated, wh...
Redeye’s analyst provides an update following the NextCell's year-end report, which also marks the t...
Efter den misslyckade satsningen mot elbilar återgår CTEK till kärnaffären: premiumladdare för lågvo...
* Exercise of warrants and a directed share issue extends runway * Phase II clinical trial expected ...
CEO Michael-Robin Witt answers questions about the Q4 report and discusses other recent news with Vä...
Voi, som är det näst största innehavet i VNV Global, kom med en mycket stark Q4-rapport.
Redeye returns with an update following AlzeCure’s Q4 2025 earnings release.
Redeye provides an update on Saniona after the company's Q4 report, which offered few surprises.
